Alector (ALEC) Competitors

Autolus Therapeutics (NASDAQ:AUTL) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, community ranking, institutional ownership, analyst recommendations and media sentiment.

Do analysts rate AUTL or ALEC?

Autolus Therapeutics presently has a consensus target price of $9.32, suggesting a potential upside of 592.94%. Alector has a consensus target price of $3.50, suggesting a potential upside of 188.07%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Autolus Therapeutics is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Alector	2 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.14

Does the MarketBeat Community prefer AUTL or ALEC?

Autolus Therapeutics received 74 more outperform votes than Alector when rated by MarketBeat users. Likewise, 68.25% of users gave Autolus Therapeutics an outperform vote while only 60.94% of users gave Alector an outperform vote.

Company	Underperform	Outperform
Autolus Therapeutics	Outperform Votes 230 68.25%	Underperform Votes 107 31.75%
Alector	Outperform Votes 156 60.94%	Underperform Votes 100 39.06%

Does the media favor AUTL or ALEC?

In the previous week, Autolus Therapeutics had 8 more articles in the media than Alector. MarketBeat recorded 13 mentions for Autolus Therapeutics and 5 mentions for Alector. Alector's average media sentiment score of 1.37 beat Autolus Therapeutics' score of 1.16 indicating that Alector is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alector	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders believe in AUTL or ALEC?

72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by company insiders. Comparatively, 9.1% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has more risk and volatility, AUTL or ALEC?

Autolus Therapeutics has a beta of 2.06, indicating that its share price is 106% more volatile than the S&P 500. Comparatively, Alector has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500.

Is AUTL or ALEC more profitable?

Autolus Therapeutics has a net margin of 0.00% compared to Alector's net margin of -257.54%. Autolus Therapeutics' return on equity of -63.65% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	N/A	-63.65%	-36.54%
Alector	-257.54%	-108.77%	-27.03%

Which has preferable earnings & valuation, AUTL or ALEC?

Alector has higher revenue and earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$10.12M	35.37	-$208.38M	-$0.86	-1.56
Alector	$100.56M	1.20	-$130.39M	-$1.23	-0.99

Summary

Autolus Therapeutics beats Alector on 12 of the 18 factors compared between the two stocks.